Brief: Revive Therapeutics Provides Update Of Phase 3 Clinical Study For Bucillamine In The Treatment Of Covid-19
30/05/2023 12:45
May 30 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE OF PHASE 3 CLINICAL
STUDY
FOR BUCILLAMINE IN THE TREATMENT OF COVID-19
* REVIVE THERAPEUTICS LTD - COMMITTED TO ADVANCING CLINICAL
AND
COMMERCIAL DEVELOPMENT OF BUCILLAMINE
Source text for Eikon: ID:nGNX4spp8b
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure